| Dr Emily Drury, DO | |
|
600 Ridgely Ave Ste 110, Annapolis, MD 21401-1082 | |
| (410) 573-9191 | |
| Not Available |
| Full Name | Dr Emily Drury |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Location | 600 Ridgely Ave Ste 110, Annapolis, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285124891 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | H96726 (Maryland) | Primary |
| Entity Name | Mid-atlantic Ent |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770175978 PECOS PAC ID: 8527477819 Enrollment ID: O20210518001076 |
News Archive
It seems that women become addicted to cocaine more easily than men and find it harder to give up. New research published in BioMed Central's open access journal Biology of Sex Differences reinforces this position by showing that the motivation of female rats to work for cocaine is much higher than males.
Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.
With human and financial resources deployed to fight the continuing COVID-19 pandemic, there is no doubt that healthcare services are facing major disruption.
CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emily Drury, DO 600 Ridgely Ave Ste 110, Annapolis, MD 21401-1082 Ph: (410) 573-9191 | Dr Emily Drury, DO 600 Ridgely Ave Ste 110, Annapolis, MD 21401-1082 Ph: (410) 573-9191 |
News Archive
It seems that women become addicted to cocaine more easily than men and find it harder to give up. New research published in BioMed Central's open access journal Biology of Sex Differences reinforces this position by showing that the motivation of female rats to work for cocaine is much higher than males.
Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.
With human and financial resources deployed to fight the continuing COVID-19 pandemic, there is no doubt that healthcare services are facing major disruption.
CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
› Verified 2 days ago
Dr. Henry Daniel Sandel Iv, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 127 Lubrano Dr, Suite 102, Annapolis, MD 21401 Phone: 410-266-7120 Fax: 410-266-6042 | |
Annalisa Debacco Overstreet, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy Ste 230, Annapolis, MD 21401 Phone: 410-266-3900 Fax: 410-266-9245 | |
Dr. Kevin Shaigany, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy Ste 230, Annapolis, MD 21401 Phone: 410-266-3900 Fax: 410-266-9245 | |
Dr. Robert Baxter Meek Iii, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 600 Ridgely Ave, Suite 110, Annapolis, MD 21401 Phone: 410-573-9191 Fax: 410-573-5910 | |
Dr. Namita Murthy, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 2629 Riva Rd Ste 108-109, Annapolis, MD 21401 Phone: 443-333-8083 | |
Douglas Alan Finnegan, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 600 Ridgely Ave, Suite 230, Annapolis, MD 21401 Phone: 410-573-9191 |